Trial Profile
A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Anal cancer; Carcinoma; Malignant fibrous histiocytoma; Malignant melanoma; Osteosarcoma; Ovarian cancer; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 25 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 25 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 30 Jun 2022.
- 07 Sep 2021 Planned primary completion date changed from 31 May 2021 to 31 Dec 2021.